Evotec has extended and expanded its medicinal chemistry collaboration with Active Biotech to advance a program that has entered lead optimization. The program aims to find small molecule modulators for a biological target selected by Active Biotech related to immune disorders and cancer. Financial details were not disclosed. The program was initiated in 2010 with a high throughput screen followed by hit validation and hit-to-lead activities, leveraging Evotec’s hit identification and integrate...